By Chelsea Naso ( October 30, 2015, 8:35 PM EDT) -- Pharmaceutical giant Pfizer's latest cross-border pursuit is already reigniting the discussion of so-called inversions roughly a year after rules surrounding the tax-motivated deal structure were tightened, posing a potential threat to a deal that has yet to even materialize....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.